Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major marginal zone lymphoma markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.
The marginal zone lymphoma market has been comprehensively analyzed in IMARC's new report titled "Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marginal zone lymphoma is a type of non-Hodgkin lymphoma that arises from the marginal zone B cells in the lymphoid tissue. Some of the common symptoms include painless swelling of lymph nodes, particularly in the neck, armpits, or groin, as well as various nonspecific indications, like fatigue, night sweats, unexplained weight loss, fever, etc. In a few cases, the ailment may affect extranodal sites, leading to symptoms specific to the impacted organ, such as abdominal pain, gastrointestinal bleeding, respiratory difficulties, etc. The diagnosis of marginal zone lymphoma involves a combination of clinical evaluation, imaging studies, laboratory investigations, and histopathological examination. Several diagnostic imaging tests, including computed tomography (CT) scan and positron emission tomography (PET) scan, help in evaluating the extent of disease progression and identifying affected lymph nodes as well as extranodal sites. A definitive diagnosis is made through a lymph node or tissue biopsy, followed by a histopathological examination by a pathologist, which consists of microscopic analysis, immunohistochemistry, and flow cytometry to determine the presence of lymphoma cells and classify the specific subtype of the ailment.
The rising cases of specific genetic and molecular alterations that can disrupt normal cellular processes and interfere with the regulation of signaling pathways involved in cell survival and immune responses are primarily driving the marginal zone lymphoma market. In addition to this, the escalating utilization of localized radiation therapy, which involves directing high-energy beams to the affected lymph nodes or organs, for controlling the disease and providing long-term remission is creating a positive outlook for the market. Moreover, the inflating adoption of stem cell transplantation for replacing diseased bone marrow with stem cells to allow the production of new, healthy blood cells is also bolstering the market growth. Additionally, the rising demand for antibody-drug conjugates for treating the ailment on account of their several associated benefits, including enhanced efficacy, targeted therapy, reduced systemic toxicity, etc., is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of cytogenetic analysis, such as chromosomal microarray analysis (CMA), since it aids in detecting chromosomal aberrations, including translocations or deletions, that can help in providing prognostic information and differentiating the ailment from other lymphoma subtypes, is expected to drive the marginal zone lymphoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the marginal zone lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for marginal zone lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the marginal zone lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the marginal zone lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the marginal zone lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current marginal zone lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the marginal zone lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the marginal zone lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the marginal zone lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with marginal zone lymphoma across the seven major markets?
What is the size of the marginal zone lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of marginal zone lymphoma?
What will be the growth rate of patients across the seven major markets?
Marginal Zone Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for marginal zone lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the marginal zone lymphoma market?
What are the key regulatory events related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by status related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by phase related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the marginal zone lymphoma market?
The marginal zone lymphoma market has been comprehensively analyzed in IMARC's new report titled "Marginal Zone Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Marginal zone lymphoma is a type of non-Hodgkin lymphoma that arises from the marginal zone B cells in the lymphoid tissue. Some of the common symptoms include painless swelling of lymph nodes, particularly in the neck, armpits, or groin, as well as various nonspecific indications, like fatigue, night sweats, unexplained weight loss, fever, etc. In a few cases, the ailment may affect extranodal sites, leading to symptoms specific to the impacted organ, such as abdominal pain, gastrointestinal bleeding, respiratory difficulties, etc. The diagnosis of marginal zone lymphoma involves a combination of clinical evaluation, imaging studies, laboratory investigations, and histopathological examination. Several diagnostic imaging tests, including computed tomography (CT) scan and positron emission tomography (PET) scan, help in evaluating the extent of disease progression and identifying affected lymph nodes as well as extranodal sites. A definitive diagnosis is made through a lymph node or tissue biopsy, followed by a histopathological examination by a pathologist, which consists of microscopic analysis, immunohistochemistry, and flow cytometry to determine the presence of lymphoma cells and classify the specific subtype of the ailment.
The rising cases of specific genetic and molecular alterations that can disrupt normal cellular processes and interfere with the regulation of signaling pathways involved in cell survival and immune responses are primarily driving the marginal zone lymphoma market. In addition to this, the escalating utilization of localized radiation therapy, which involves directing high-energy beams to the affected lymph nodes or organs, for controlling the disease and providing long-term remission is creating a positive outlook for the market. Moreover, the inflating adoption of stem cell transplantation for replacing diseased bone marrow with stem cells to allow the production of new, healthy blood cells is also bolstering the market growth. Additionally, the rising demand for antibody-drug conjugates for treating the ailment on account of their several associated benefits, including enhanced efficacy, targeted therapy, reduced systemic toxicity, etc., is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of cytogenetic analysis, such as chromosomal microarray analysis (CMA), since it aids in detecting chromosomal aberrations, including translocations or deletions, that can help in providing prognostic information and differentiating the ailment from other lymphoma subtypes, is expected to drive the marginal zone lymphoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the marginal zone lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for marginal zone lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the marginal zone lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the marginal zone lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the marginal zone lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current marginal zone lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the marginal zone lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the marginal zone lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the marginal zone lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of marginal zone lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with marginal zone lymphoma across the seven major markets?
What is the size of the marginal zone lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of marginal zone lymphoma?
What will be the growth rate of patients across the seven major markets?
Marginal Zone Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for marginal zone lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the marginal zone lymphoma market?
What are the key regulatory events related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by status related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by phase related to the marginal zone lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the marginal zone lymphoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MARGINAL ZONE LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MARGINAL ZONE LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MARGINAL ZONE LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6 5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MARGINAL ZONE LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MARGINAL ZONE LYMPHOMA - UNMET NEEDS
10 MARGINAL ZONE LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 MARGINAL ZONE LYMPHOMA - MARKETED PRODUCTS
11.1 List of Marginal Zone Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Brukinsa (Zanubrutinib) - BeiGene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Revlimid (Lenalidomide) - Celgene Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MARGINAL ZONE LYMPHOMA - PIPELINE DRUGS
12.1 List of Marginal Zone Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Loncastuximab tesirine - ADC Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tafasitamab - Incyte Corporation/MorphoSys
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Orelabrutinib - InnoCare Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MARGINAL ZONE LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MARGINAL ZONE LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MARGINAL ZONE LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Marginal Zone Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Marginal Zone Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Marginal Zone Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Marginal Zone Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Marginal Zone Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Marginal Zone Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Marginal Zone Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Marginal Zone Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Marginal Zone Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Marginal Zone Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Marginal Zone Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Marginal Zone Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Marginal Zone Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Marginal Zone Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Marginal Zone Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Marginal Zone Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
16 MARGINAL ZONE LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MARGINAL ZONE LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MARGINAL ZONE LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MARGINAL ZONE LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MARGINAL ZONE LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MARGINAL ZONE LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6 5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MARGINAL ZONE LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MARGINAL ZONE LYMPHOMA - UNMET NEEDS
10 MARGINAL ZONE LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 MARGINAL ZONE LYMPHOMA - MARKETED PRODUCTS
11.1 List of Marginal Zone Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Brukinsa (Zanubrutinib) - BeiGene
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Revlimid (Lenalidomide) - Celgene Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MARGINAL ZONE LYMPHOMA - PIPELINE DRUGS
12.1 List of Marginal Zone Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Loncastuximab tesirine - ADC Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Tafasitamab - Incyte Corporation/MorphoSys
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Orelabrutinib - InnoCare Pharma
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MARGINAL ZONE LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MARGINAL ZONE LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MARGINAL ZONE LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Marginal Zone Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Marginal Zone Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Marginal Zone Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Marginal Zone Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Marginal Zone Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Marginal Zone Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Marginal Zone Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Marginal Zone Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Marginal Zone Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Marginal Zone Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Marginal Zone Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Marginal Zone Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Marginal Zone Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Marginal Zone Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Marginal Zone Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Marginal Zone Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Marginal Zone Lymphoma - Access and Reimbursement Overview
16 MARGINAL ZONE LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MARGINAL ZONE LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MARGINAL ZONE LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
